Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELOSEF '250' (cephradine) is an oral cephalosporin antibiotic in capsule form developed by Teva. It is indicated for bacterial infections across respiratory, urinary, and soft-tissue sites. Cephradine is a first-generation cephalosporin that inhibits bacterial cell wall synthesis.
Pre-Launch
Early-stage launch preparation offers opportunity to shape commercial strategy, but limited market intelligence is available at this stage.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Joining the VELOSEF '250' team offers entry or mid-career opportunity in specialty pharmaceutical launch execution, with focus on competitive positioning in a generic-dominated market. Career progression will depend on successful commercial performance and ability to drive adoption in a price-sensitive antibiotic category.
Brand ManagerField Sales Representative
Worked on VELOSEF '250' at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.